IN2014CN03250A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03250A
IN2014CN03250A IN3250CHN2014A IN2014CN03250A IN 2014CN03250 A IN2014CN03250 A IN 2014CN03250A IN 3250CHN2014 A IN3250CHN2014 A IN 3250CHN2014A IN 2014CN03250 A IN2014CN03250 A IN 2014CN03250A
Authority
IN
India
Prior art keywords
formula
pyridone
compounds
btk kinase
disorders
Prior art date
Application number
Other languages
English (en)
Inventor
James John Crawford
Daniel Fred Ortwine
Binqing Wei
Wendy B Young
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2014CN03250A publication Critical patent/IN2014CN03250A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN3250CHN2014 2011-11-03 2012-11-02 IN2014CN03250A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555393P 2011-11-03 2011-11-03
PCT/US2012/063194 WO2013067274A1 (en) 2011-11-03 2012-11-02 Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Publications (1)

Publication Number Publication Date
IN2014CN03250A true IN2014CN03250A (enrdf_load_stackoverflow) 2015-07-03

Family

ID=47146779

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3250CHN2014 IN2014CN03250A (enrdf_load_stackoverflow) 2011-11-03 2012-11-02

Country Status (34)

Country Link
US (11) US8716274B2 (enrdf_load_stackoverflow)
EP (5) EP4050012A1 (enrdf_load_stackoverflow)
JP (5) JP5976827B2 (enrdf_load_stackoverflow)
KR (2) KR20160003328A (enrdf_load_stackoverflow)
CN (2) CN107011348B (enrdf_load_stackoverflow)
AR (2) AR088641A1 (enrdf_load_stackoverflow)
AU (5) AU2012332365B2 (enrdf_load_stackoverflow)
CA (1) CA2853975C (enrdf_load_stackoverflow)
CL (1) CL2014001103A1 (enrdf_load_stackoverflow)
CO (1) CO6950472A2 (enrdf_load_stackoverflow)
CR (1) CR20140194A (enrdf_load_stackoverflow)
CY (1) CY1117097T1 (enrdf_load_stackoverflow)
DK (2) DK2773638T3 (enrdf_load_stackoverflow)
EA (1) EA023263B1 (enrdf_load_stackoverflow)
ES (3) ES2898938T3 (enrdf_load_stackoverflow)
HR (2) HRP20151442T1 (enrdf_load_stackoverflow)
HU (2) HUE044959T2 (enrdf_load_stackoverflow)
IL (1) IL232060A (enrdf_load_stackoverflow)
IN (1) IN2014CN03250A (enrdf_load_stackoverflow)
LT (1) LT3002284T (enrdf_load_stackoverflow)
MA (1) MA35819B1 (enrdf_load_stackoverflow)
MX (2) MX361807B (enrdf_load_stackoverflow)
PE (1) PE20141586A1 (enrdf_load_stackoverflow)
PH (1) PH12014500936A1 (enrdf_load_stackoverflow)
PL (3) PL3521288T3 (enrdf_load_stackoverflow)
PT (2) PT2773638E (enrdf_load_stackoverflow)
RS (2) RS59016B1 (enrdf_load_stackoverflow)
SG (1) SG11201401992YA (enrdf_load_stackoverflow)
SI (2) SI3002284T1 (enrdf_load_stackoverflow)
TR (1) TR201909849T4 (enrdf_load_stackoverflow)
TW (4) TW202124384A (enrdf_load_stackoverflow)
UA (1) UA111756C2 (enrdf_load_stackoverflow)
WO (1) WO2013067274A1 (enrdf_load_stackoverflow)
ZA (1) ZA201804727B (enrdf_load_stackoverflow)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR088642A1 (es) * 2011-11-03 2014-06-25 Genentech Inc Compuestos de piperazina alquilados
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
CN110698481B (zh) * 2013-07-03 2023-02-28 豪夫迈·罗氏有限公司 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
WO2015050703A1 (en) * 2013-10-04 2015-04-09 Yi Chen Inhibitors of bruton's tyrosine kinase
RU2646758C2 (ru) 2013-12-05 2018-03-07 Ф. Хоффманн-Ля Рош Аг Гетероарил пиридоны и азапиридоны с электрофильной функциональностью
EP3201186B1 (en) * 2014-10-02 2019-02-27 F. Hoffmann-La Roche AG Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
CN111747956A (zh) * 2014-10-27 2020-10-09 豪夫迈·罗氏有限公司 制备三环内酰胺化合物的方法
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
AR105875A1 (es) 2015-09-02 2017-11-15 GLAXOSMITHKLINE INTELLECTUAL PROPERTY (Nº 2) LTD Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio
CA3002560A1 (en) 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
ES2897913T3 (es) * 2016-02-19 2022-03-03 Novartis Ag Compuestos de piridona tetracíclicos como antivirales
KR20200118507A (ko) * 2016-02-29 2020-10-15 에프. 호프만-라 로슈 아게 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물
CN108473510B (zh) * 2016-04-28 2021-10-29 豪夫迈·罗氏有限公司 制备2-吡唑并[1,5-a]吡嗪-2-基吡啶并[1,2-a]嘧啶-4-酮的方法
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
AU2017368331A1 (en) 2016-12-03 2019-06-13 Acerta Pharma B.V. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
JP2020510624A (ja) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
JP6800334B2 (ja) * 2016-12-15 2020-12-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂｔｋ阻害剤を調製するプロセス
DK3559000T3 (da) 2016-12-22 2022-06-07 Betta Pharmaceuticals Co Ltd Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf
JP2020514384A (ja) * 2017-03-24 2020-05-21 ジェネンテック， インコーポレイテッド 自己免疫及び炎症性疾患を治療する方法
CN107445981B (zh) * 2017-08-25 2018-06-22 牡丹江医学院 一种用于防治宫颈炎的活性化合物
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
KR20200057705A (ko) 2017-10-27 2020-05-26 프레세니어스 카비 온콜로지 리미티드 리보시클립 및 그의 염의 제조를 위한 개선된 방법
US11100492B2 (en) 2018-02-19 2021-08-24 Peter Garrett General purpose re-loadable card aggregation implementation
TWI801517B (zh) 2018-03-12 2023-05-11 加拿大商愛彼特生物製藥公司 經取代的2-吡啶酮三環化合物、其類似物及其使用方法
JP7331843B2 (ja) 2018-04-27 2023-08-23 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
PE20210406A1 (es) 2018-07-25 2021-03-02 Novartis Ag Inhibidores de inflamasoma nlrp3
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
CA3111126A1 (en) 2018-08-31 2020-03-05 Stichting Katholieke Universiteit Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
CN118955473A (zh) 2018-10-15 2024-11-15 紐力克斯治疗公司 通过泛素蛋白酶体途径降解btk的双官能化合物
JP7212781B2 (ja) 2018-12-19 2023-01-25 ディスアーム セラピューティクス， インコーポレイテッド 神経保護剤と組み合わせたｓａｒｍ１の阻害剤
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
TW202033523A (zh) * 2019-01-17 2020-09-16 美商愛彼特生物製藥股份有限公司 經取代的多環羧酸、其類似物及使用其之方法
TW202042815A (zh) 2019-01-22 2020-12-01 美商建南德克公司 使用布魯頓（bruton）酪胺酸激酶抑制劑治療類風性關節炎、慢性自發性蕁麻疹及全身性紅斑性狼瘡的方法
US20220135569A1 (en) 2019-02-25 2022-05-05 Newave Pharmaceutical Inc. Inhibitor of btk and mutants thereof
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
EP3953346A1 (en) 2019-04-09 2022-02-16 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
CN114206855B (zh) 2019-05-17 2024-11-26 紐力克斯治疗公司 用于Cbl-b抑制的氰基环丁基类化合物及其用途
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
AU2020303696A1 (en) 2019-06-26 2022-01-06 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
WO2021066958A1 (en) 2019-10-05 2021-04-08 Newave Pharmaceutical Inc. Inhibitor of btk and mutants thereof
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021091575A1 (en) * 2019-11-08 2021-05-14 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
US11820781B2 (en) 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2023515099A (ja) * 2020-02-20 2023-04-12 ハチソン メディファーマ リミテッド ヘテロアリール複素環式化合物およびその使用
US20230091561A1 (en) 2020-02-28 2023-03-23 Genentech, Inc. Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase
IL296990A (en) 2020-04-03 2022-12-01 Genentech Inc Methods for the treatment of multiple sclerosis relapse using an inhibitor of proton tyrosine kinase
CN115715291B (zh) * 2020-06-18 2025-04-29 上海华汇拓医药科技有限公司 布鲁顿酪氨酸激酶抑制剂及其制备方法
JP2023536339A (ja) * 2020-08-04 2023-08-24 エフ． ホフマン－ラ ロシュ アーゲー 自己免疫疾患の処置のためのピリジノン化合物
CA3185469A1 (en) 2020-08-14 2022-02-17 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
JP2023537626A (ja) * 2020-08-14 2023-09-04 グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド Ｂｔｋ及びその変異体の阻害剤を含む剤形組成物
IL301275A (en) 2020-09-21 2023-05-01 Hutchison Medipharma Ltd Heteroaryl heterocyclic compounds and uses thereof
US20230382900A1 (en) 2020-10-30 2023-11-30 Newave Pharmaceutical Inc. Inhibitors of btk
EP4263552A1 (en) 2020-12-20 2023-10-25 Guangzhou Lupeng Pharmaceutical Company Ltd. Btk degrader
US20240216330A1 (en) 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
AU2022254104A1 (en) 2021-04-08 2023-10-26 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds
JP2024517004A (ja) 2021-05-05 2024-04-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｂｔｋ阻害剤を調製するための方法
CN113603685A (zh) * 2021-07-23 2021-11-05 都创(上海)医药开发有限公司 Fenebrutinib化合物的晶型及其制备方法和用途
EP4422630A1 (en) 2021-10-26 2024-09-04 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors
US20250136620A1 (en) * 2022-01-17 2025-05-01 Newave Pharmaceutical Inc. Btk degrader
TW202346276A (zh) 2022-01-27 2023-12-01 日商田邊三菱製藥股份有限公司 新穎之ｂ０ａｔ１抑制劑
JP2025504938A (ja) 2022-01-28 2025-02-19 ハチメド リミテッド ７，８－ジヒドロ－２ｈ－シクロペンタピロロピラジノン化合物の合成方法
AR130094A1 (es) 2022-08-03 2024-10-30 Novartis Ag Inhibidores de inflamasoma nlrp3
TW202508592A (zh) 2023-05-16 2025-03-01 美商建南德克公司 使用布魯頓酪胺酸激酶之抑制劑來治療復發型多發性硬化症之方法
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
WO2025031344A1 (zh) * 2023-08-07 2025-02-13 广州麓鹏制药有限公司 一种丙烯酰胺类化合物的晶型vi及其制备方法和用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
ES2579402T3 (es) 2001-07-12 2016-08-11 Reaxa Limited Catalizador microencapsulado, métodos de preparación y métodos de uso de este
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
CA2587192A1 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
US7947835B2 (en) 2005-03-10 2011-05-24 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
RS51782B (en) 2005-10-07 2011-12-31 Exelixis Inc. AZETIDINS AS MAK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PT2526933E (pt) * 2006-09-22 2015-06-23 Pharmacyclics Inc Inibidores da tirosina-quinase de bruton
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2009053269A1 (en) * 2007-10-23 2009-04-30 F. Hoffmann-La Roche Ag Novel kinase inhibitors
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
KR101308803B1 (ko) * 2008-02-05 2013-09-13 에프. 호프만-라 로슈 아게 신규한 피리디논 및 피리다지논
WO2009137596A1 (en) 2008-05-06 2009-11-12 Cgi Pharmaceuticals, Inc. Substituted amides, method of making, and use as btk inhibitors
BRPI0914657A2 (pt) 2008-06-24 2019-09-24 F Hoffmann La Roche piridin-2-onae piridazin-3-onas substituídas
RU2507202C2 (ru) 2008-07-02 2014-02-20 Ф.Хоффманн-Ля Рош Аг Новые фенилпиразиноны в качестве ингибиторов киназы
CA2636807A1 (en) 2008-07-04 2010-01-04 Steven Splinter Methods for obtaining cyclopamine
JP5318952B2 (ja) 2008-07-15 2013-10-16 エフ．ホフマン−ラ ロシュ アーゲー 新規なフェニル−イミダゾピリジン類及びピリダジン類
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
ES2513915T3 (es) * 2009-04-24 2014-10-27 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
US8765754B2 (en) * 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CN102711473B (zh) * 2009-09-04 2016-11-09 比奥根Ma公司 布鲁顿酪氨酸激酶抑制剂
CN107253963B (zh) * 2010-05-07 2020-04-14 吉利德康涅狄格有限公司 吡啶酮和氮杂吡啶酮化合物及使用方法
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
CN103201277B (zh) 2010-09-01 2015-11-25 吉利德康涅狄格有限公司 哒嗪酮、其制备方法及使用方法
KR101837223B1 (ko) 2010-09-01 2018-03-09 질레드 코네티컷 인코포레이티드 피리디논/피라지논, 그의 제조 방법 및 사용 방법
PH12013502379A1 (en) 2011-05-17 2014-01-13 Hoffmann La Roche Inhibitors of bruton's tyrosine kinase
CA2841801A1 (en) * 2011-08-17 2013-02-21 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
AR088642A1 (es) * 2011-11-03 2014-06-25 Genentech Inc Compuestos de piperazina alquilados
AR088643A1 (es) * 2011-11-03 2014-06-25 Genentech Inc Compuestos de 8-fluoroftalazin-1(2h)-ona
CN110698481B (zh) * 2013-07-03 2023-02-28 豪夫迈·罗氏有限公司 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
RU2646758C2 (ru) * 2013-12-05 2018-03-07 Ф. Хоффманн-Ля Рош Аг Гетероарил пиридоны и азапиридоны с электрофильной функциональностью
KR20200118507A (ko) * 2016-02-29 2020-10-15 에프. 호프만-라 로슈 아게 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물

Also Published As

Publication number Publication date
KR20140096097A (ko) 2014-08-04
EP2773638B1 (en) 2015-10-07
CN107011348B (zh) 2020-01-10
EP3521288A1 (en) 2019-08-07
EP3521288B1 (en) 2021-09-08
US20140378432A1 (en) 2014-12-25
BR112014010459A2 (pt) 2017-04-18
UA111756C2 (uk) 2016-06-10
TWI701250B (zh) 2020-08-11
TW202124384A (zh) 2021-07-01
IL232060A0 (en) 2014-05-28
EP3002284B1 (en) 2019-05-22
MA35819B1 (fr) 2014-12-01
AU2016273930B2 (en) 2018-03-08
MX2014005331A (es) 2014-05-28
PL2773638T3 (pl) 2016-03-31
CA2853975C (en) 2020-02-25
AU2016273930A1 (en) 2017-01-12
TW201741315A (zh) 2017-12-01
JP2014532762A (ja) 2014-12-08
HUE044959T2 (hu) 2019-12-30
JP2016028046A (ja) 2016-02-25
IL232060A (en) 2016-02-29
US20230279012A1 (en) 2023-09-07
US9238655B2 (en) 2016-01-19
TR201909849T4 (tr) 2019-07-22
AR088641A1 (es) 2014-06-25
JP5976827B2 (ja) 2016-08-24
PH12014500936A1 (en) 2014-06-09
WO2013067274A1 (en) 2013-05-10
ES2738329T3 (es) 2020-01-22
PT2773638E (pt) 2016-01-12
CN104125959A (zh) 2014-10-29
US20180071286A1 (en) 2018-03-15
AU2012332365B2 (en) 2016-09-15
MX361807B (es) 2018-12-17
US20130116235A1 (en) 2013-05-09
HK1201265A1 (en) 2015-08-28
AU2020202707A1 (en) 2020-05-14
PL3002284T3 (pl) 2019-11-29
CR20140194A (es) 2014-06-03
EP2773638A1 (en) 2014-09-10
PT3002284T (pt) 2019-07-17
PE20141586A1 (es) 2014-10-25
DK3002284T3 (da) 2019-07-29
SI3002284T1 (sl) 2019-08-30
TW201906845A (zh) 2019-02-16
RS59016B1 (sr) 2019-08-30
CN104125959B (zh) 2017-05-03
ES2898938T3 (es) 2022-03-09
HUE028019T2 (en) 2016-11-28
EA023263B1 (ru) 2016-05-31
CO6950472A2 (es) 2014-05-20
CY1117097T1 (el) 2017-04-05
PL3521288T3 (pl) 2021-12-27
AR117501A2 (es) 2021-08-11
AU2020202707B2 (en) 2021-09-02
JP2020183397A (ja) 2020-11-12
AU2018201557A1 (en) 2018-03-22
JP2019108342A (ja) 2019-07-04
ES2555168T3 (es) 2015-12-29
CN107011348A (zh) 2017-08-04
EP4050012A1 (en) 2022-08-31
US8716274B2 (en) 2014-05-06
TW201326175A (zh) 2013-07-01
USRE48239E1 (en) 2020-10-06
AU2012332365A1 (en) 2014-05-01
US20240270747A1 (en) 2024-08-15
KR101659193B1 (ko) 2016-09-22
US20140194408A1 (en) 2014-07-10
ZA201804727B (en) 2023-03-29
EP3002284A1 (en) 2016-04-06
AU2019216728A1 (en) 2019-09-05
US9782405B2 (en) 2017-10-10
DK2773638T3 (en) 2015-10-19
US20200062769A1 (en) 2020-02-27
CL2014001103A1 (es) 2014-10-03
US20160228432A1 (en) 2016-08-11
US20190194203A1 (en) 2019-06-27
LT3002284T (lt) 2019-08-12
EP4019508A1 (en) 2022-06-29
AU2019216728B2 (en) 2020-04-09
TWI609868B (zh) 2018-01-01
CA2853975A1 (en) 2013-05-10
US10045983B2 (en) 2018-08-14
SG11201401992YA (en) 2014-05-29
SI2773638T1 (sl) 2015-12-31
HRP20151442T1 (hr) 2016-01-29
US20210079002A1 (en) 2021-03-18
NZ624021A (en) 2016-09-30
US8921353B2 (en) 2014-12-30
TWI652270B (zh) 2019-03-01
HRP20191307T1 (hr) 2019-10-18
JP6571215B2 (ja) 2019-09-04
RS54505B1 (en) 2016-06-30
JP2018080193A (ja) 2018-05-24
AU2018201557B2 (en) 2019-09-19
KR20160003328A (ko) 2016-01-08
EA201490858A1 (ru) 2014-08-29

Similar Documents

Publication Publication Date Title
IN2014CN03250A (enrdf_load_stackoverflow)
MY160349A (en) Pyridone and aza-pyridone compounds and methods of use
IN2014CN03265A (enrdf_load_stackoverflow)
MX2014005285A (es) Compuestos biciclicos de piperazina.
MX2014005282A (es) Compuestos de 8-fluoroftalazin-1 (2h) -ona.
MX2016007171A (es) Compuestos de heteroaril piridona y azapiridona con funcionalidad electrofila.
MX2015018038A (es) Compuestos de heteroaril-piridona y aza-piridona-amida.
MX2014001239A (es) Compuestos de pirazolo [3,4-c] piridina y metodos de uso.
MX2014014828A (es) Compuestos de 5-azaindazol y metodos de uso.
PH12015500488A1 (en) Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
MX340013B (es) Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
PH12012501864A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
BR112013020329A2 (pt) compostos heterocíclicos como inibidores da pi3-quinase
PH12013502445A1 (en) Pyridin-2 (1h) -one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
MX350112B (es) Derivados de furo[3,2-b]- y tieno[3,2-b]piridina como inhibidores de tbk1 e ikk.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX345127B (es) Derivados de tiazol.
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
PH12015500063A1 (en) Azaindole derivatives which act as pi3k inhibitors
IN2014CN04065A (enrdf_load_stackoverflow)
MY166463A (en) Positive allosteric modulators of nicotinic acetylcholine receptor
MX2016012007A (es) Compuestos de oxepan-2-il-pirazol-4-il-heterociclil-carboxamida y metodos de uso.
NZ620928A (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
MA42864B1 (fr) Composes d’éther cyclique-pyrazol-4-yl-heterocyclyl-carboxamide et procédés d'utilisation